Demographic and clinical characteristics of study patients (women aged <60 years) at study entry
| Characteristic . | No hormonal use during period at risk (n = 1413) . | Any hormonal use during period at risk (n = 475) . | Estrogen-containing therapy (n = 306)* . | Progestin-only therapy (n = 217)* . |
|---|---|---|---|---|
| Age, years, mean (SD) | 42.9 (11.3) | 36.6 (10.4) | 37.3 (10.3) | 35.4 (10.1) |
| Age, n (%) | ||||
| <40 years | 494 (35.0) | 270 (56.8) | 167 (54.6) | 135 (62.2) |
| ≥40 years | 919 (65.0) | 205 (43.2) | 139 (45.4) | 82 (37.8) |
| Creatinine clearance, ml/min, mean (SD) | 119.2 (41.3) | 127.6 (40.4) | 127.2 (39.9) | 130.4 (40.8) |
| BMI, mean (SD) | 28.4 (7.3) | 27.3 (7.0) | 27.2 (6.4) | 27.8 (7.8) |
| Index event, n (%) | ||||
| DVT | 644 (45.6) | 193 (40.6) | 139 (45.4) | 67 (30.9) |
| PE ± DVT | 769 (54.4) | 282 (59.4) | 167 (54.6) | 150 (69.1) |
| Planned treatment duration, n (%) | ||||
| 3 months | 146 (10.3) | 54 (11.4) | 37 (12.1) | 20 (9.2) |
| 6 months | 880 (62.3) | 330 (69.5) | 215 (70.3) | 149 (68.7) |
| 12 months | 387 (27.4) | 91 (19.2) | 54 (17.6) | 48 (22.1) |
| Active cancer (%) | 61 (4.3) | 6 (1.3) | 6 (2.0) | 0 |
| History of DVT/PE (%) | 230 (16.3) | 41 (8.6) | 14 (4.6) | 29 (13.4) |
| Use during at-risk period (%) | ||||
| Antiplatelet therapy | 110 (7.8) | 15 (3.2) | 7 (2.3) | 10 (4.6) |
| NSAIDs | 301 (21.3) | 94 (19.8) | 54 (17.6) | 53 (24.4) |
| Antifibrinolytic therapy | 11 (0.8) | 2 (0.4) | 1 (0.3) | 1 (0.5) |
| Anemia (%) | 406 (28.7) | 98 (20.6) | 60 (19.6) | 42 (19.4) |
| Gynecologic disorders (%)† | 66 (4.7) | 17 (3.6) | 13 (4.2) | 5 (2.3) |
| Characteristic . | No hormonal use during period at risk (n = 1413) . | Any hormonal use during period at risk (n = 475) . | Estrogen-containing therapy (n = 306)* . | Progestin-only therapy (n = 217)* . |
|---|---|---|---|---|
| Age, years, mean (SD) | 42.9 (11.3) | 36.6 (10.4) | 37.3 (10.3) | 35.4 (10.1) |
| Age, n (%) | ||||
| <40 years | 494 (35.0) | 270 (56.8) | 167 (54.6) | 135 (62.2) |
| ≥40 years | 919 (65.0) | 205 (43.2) | 139 (45.4) | 82 (37.8) |
| Creatinine clearance, ml/min, mean (SD) | 119.2 (41.3) | 127.6 (40.4) | 127.2 (39.9) | 130.4 (40.8) |
| BMI, mean (SD) | 28.4 (7.3) | 27.3 (7.0) | 27.2 (6.4) | 27.8 (7.8) |
| Index event, n (%) | ||||
| DVT | 644 (45.6) | 193 (40.6) | 139 (45.4) | 67 (30.9) |
| PE ± DVT | 769 (54.4) | 282 (59.4) | 167 (54.6) | 150 (69.1) |
| Planned treatment duration, n (%) | ||||
| 3 months | 146 (10.3) | 54 (11.4) | 37 (12.1) | 20 (9.2) |
| 6 months | 880 (62.3) | 330 (69.5) | 215 (70.3) | 149 (68.7) |
| 12 months | 387 (27.4) | 91 (19.2) | 54 (17.6) | 48 (22.1) |
| Active cancer (%) | 61 (4.3) | 6 (1.3) | 6 (2.0) | 0 |
| History of DVT/PE (%) | 230 (16.3) | 41 (8.6) | 14 (4.6) | 29 (13.4) |
| Use during at-risk period (%) | ||||
| Antiplatelet therapy | 110 (7.8) | 15 (3.2) | 7 (2.3) | 10 (4.6) |
| NSAIDs | 301 (21.3) | 94 (19.8) | 54 (17.6) | 53 (24.4) |
| Antifibrinolytic therapy | 11 (0.8) | 2 (0.4) | 1 (0.3) | 1 (0.5) |
| Anemia (%) | 406 (28.7) | 98 (20.6) | 60 (19.6) | 42 (19.4) |
| Gynecologic disorders (%)† | 66 (4.7) | 17 (3.6) | 13 (4.2) | 5 (2.3) |